For example, in a lebrikizumab (an anti-IL-13 mAb) dose-finding study in moderate-to-severe asthma patients with high periostin levels, there was a direct correlation between exacerbation rate and lebrikizumab dose [89]. Here, IL13 is linked to asthma.